Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 417 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $74.00, for a total transaction of $30,858.00. Following the completion of the transaction, the insider directly owned 103,508 shares in the company, valued at $7,659,592. This trade represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Christopher Mutz also recently made the following trade(s):

• On Friday, February 20th, Christopher Mutz sold 5,323 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $78.02, for a total value of $415,300.46.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock traded up $0.43 during midday trading on Wednesday, reaching $76.53. The company’s stock had a trading volume of 676,665 shares, compared to its average volume of 333,651. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The stock has a market cap of $1.72 billion, a PE ratio of 22.78 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a 52 week low of $56.71 and a 52 week high of $99.50. The business has a 50-day moving average price of $79.92 and a 200-day moving average price of $86.11.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of ANIP. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. boosted its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares in the last quarter. Newbridge Financial Services Group Inc. grew its holdings in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 400 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in ANI Pharmaceuticals in the fourth quarter worth $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals in the second quarter valued at $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Finally, Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.